SARS-CoV-2 Infection during the Omicron Surge among Patients Receiving Dialysis: The Role of Circulating Receptor-Binding Domain Antibodies and Vaccine Doses.
COVID-19
ESKD
SARS-CoV-2
chronic dialysis
clinical epidemiology
immunology
Journal
Journal of the American Society of Nephrology : JASN
ISSN: 1533-3450
Titre abrégé: J Am Soc Nephrol
Pays: United States
ID NLM: 9013836
Informations de publication
Date de publication:
10 2022
10 2022
Historique:
received:
27
04
2022
accepted:
17
06
2022
pubmed:
17
8
2022
medline:
14
1
2023
entrez:
16
8
2022
Statut:
ppublish
Résumé
It is unclear whether circulating antibody levels conferred protection against SARS-CoV-2 infection among patients receiving dialysis during the Omicron-dominant period. We followed monthly semiquantitative SARS-CoV-2 RBD IgG index values in a randomly selected nationwide cohort of patients receiving dialysis and ascertained SARS-CoV-2 infection during the Omicron-dominant period of December 25, 2021 to January 31, 2022 using electronic health records. We estimated the relative risk for documented SARS-CoV-2 infection by vaccination status and by circulating RBD IgG using a log-binomial model accounting for age, sex, and prior COVID-19. Among 3576 patients receiving dialysis, 901 (25%) received a third mRNA vaccine dose as of December 24, 2021. Early antibody responses to third doses were robust (median peak index IgG value at assay limit of 150). During the Omicron-dominant period, SARS-CoV-2 infection was documented in 340 (7%) patients. Risk for infection was higher among patients without vaccination and with one to two doses (RR, 2.1; 95% CI, 1.6 to 2.8, and RR, 1.3; 95% CI, 1.0 to 1.8 versus three doses, respectively). Irrespective of the number of vaccine doses, risk for infection was higher among patients with circulating RBD IgG <23 (506 BAU/ml) (RR range, 2.1 to 3.2, 95% CI, 1.3 to 3.4 and 95% CI, 2.2 to 4.5, respectively) compared with RBD IgG ≥23. Among patients receiving dialysis, a third mRNA vaccine dose enhanced protection against SARS-CoV-2 infection during the Omicron-dominant period, but a low circulating RBD antibody response was associated with risk for infection independent of the number of vaccine doses. Measuring circulating antibody levels in this high-risk group could inform optimal timing of vaccination and other measures to reduce risk of SARS-CoV-2 infection.
Sections du résumé
BACKGROUND
It is unclear whether circulating antibody levels conferred protection against SARS-CoV-2 infection among patients receiving dialysis during the Omicron-dominant period.
METHODS
We followed monthly semiquantitative SARS-CoV-2 RBD IgG index values in a randomly selected nationwide cohort of patients receiving dialysis and ascertained SARS-CoV-2 infection during the Omicron-dominant period of December 25, 2021 to January 31, 2022 using electronic health records. We estimated the relative risk for documented SARS-CoV-2 infection by vaccination status and by circulating RBD IgG using a log-binomial model accounting for age, sex, and prior COVID-19.
RESULTS
Among 3576 patients receiving dialysis, 901 (25%) received a third mRNA vaccine dose as of December 24, 2021. Early antibody responses to third doses were robust (median peak index IgG value at assay limit of 150). During the Omicron-dominant period, SARS-CoV-2 infection was documented in 340 (7%) patients. Risk for infection was higher among patients without vaccination and with one to two doses (RR, 2.1; 95% CI, 1.6 to 2.8, and RR, 1.3; 95% CI, 1.0 to 1.8 versus three doses, respectively). Irrespective of the number of vaccine doses, risk for infection was higher among patients with circulating RBD IgG <23 (506 BAU/ml) (RR range, 2.1 to 3.2, 95% CI, 1.3 to 3.4 and 95% CI, 2.2 to 4.5, respectively) compared with RBD IgG ≥23.
CONCLUSIONS
Among patients receiving dialysis, a third mRNA vaccine dose enhanced protection against SARS-CoV-2 infection during the Omicron-dominant period, but a low circulating RBD antibody response was associated with risk for infection independent of the number of vaccine doses. Measuring circulating antibody levels in this high-risk group could inform optimal timing of vaccination and other measures to reduce risk of SARS-CoV-2 infection.
Identifiants
pubmed: 35973733
pii: 00001751-202210000-00011
doi: 10.1681/ASN.2022040504
pmc: PMC9528334
doi:
Substances chimiques
Vaccines
0
Antibodies, Viral
0
Immunoglobulin G
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1832-1839Subventions
Organisme : NIDDK NIH HHS
ID : K24 DK085446
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK127138
Pays : United States
Commentaires et corrections
Type : UpdateOf
Informations de copyright
Copyright © 2022 by the American Society of Nephrology.
Références
Anand S, Montez-Rath ME, Han J, Garcia P, Cadden L, Hunsader P, et al.: Antibody response to COVID-19 vaccination in patients receiving dialysis. J Am Soc Nephrol 32: 2435–2438, 2021
Garcia P, Anand S, Han J, Montez-Rath ME, Sun S, Shang T, et al.: COVID-19 vaccine type and humoral immune response in patients receiving dialysis. J Am Soc Nephrol 33: 33–37, 2021
Grupper A, Sharon N, Finn T, Cohen R, Israel M, Agbaria A, et al.: Humoral response to the Pfizer BNT162b2 vaccine in patients undergoing maintenance hemodialysis. Clin J Am Soc Nephrol 16: 1037–1042, 2021
Hasmann S, Paal M, Füeßl L, Fischereder M, Schönermarck U: Humoral immunity to SARS-CoV-2 vaccination in haemodialysis patients: (Response to: Humoral and cellular immunity to SARS-CoV-2 vaccination in renal transplant versus dialysis patients: A prospective, multicenter observational study using mRNA-1273 or BNT162b2 mRNA vaccine.). Lancet Reg Health Eur 10: 100237, 2021
Anand S, Montez-Rath ME, Han J, Garcia P, Cadden L, Hunsader P, et al.: SARS-CoV-2 vaccine antibody response and breakthrough infection in patients receiving dialysis. Ann Intern Med 175: 371–378, 2021
Berar-Yanay N, Freiman S, Shapira M, Saffoury A, Elemy A, Hamze M, et al.: Waning humoral response 3 to 6 months after vaccination with the SARS-COV-2 BNT162b2 mRNA vaccine in dialysis patients. J Clin Med 11: 64, 2021
Hsu CM, Weiner DE, Manley HJ, Aweh GN, Ladik V, Frament J, et al.: Seroresponse to SARS-CoV-2 vaccines among maintenance dialysis patients over 6 months. Clin J Am Soc Nephrol 17: 403–413, 2022
Boudhabhay I, Serris A, Servais A, Planas D, Hummel A, Guery B, et al.: COVID-19 outbreak in vaccinated patients from a haemodialysis unit: Antibody titres as a marker of protection from infection. Nephrol Dial Transplant 37: 1357–1365, 2022
Salerno S, Messana JM, Gremel GW, Dahlerus C, Hirth RA, Han P, et al.: COVID-19 risk factors and mortality outcomes among Medicare patients receiving long-term dialysis. JAMA Netw Open 4: e2135379, 2021
Centers for Medicare & Medicaid Services. Preliminary Medicare COVID-19 Data Snapshot, 2022. Available at: https://www.cms.gov/research-statistics-data-systems/preliminary-medicare-covid-19-data-snapshot/ . Accessed February 12, 2022.
Corbett RW, Blakey S, Nitsch D, Loucaidou M, McLean A, Duncan N, et al.: West London Renal and Transplant Centre: Epidemiology of COVID-19 in an urban dialysis center. J Am Soc Nephrol 31: 1815–1823, 2020
Centers for Disease Control and Prevention: COVID Data Tracker. Available at: https://covid.cdc.gov/covid-data-tracker/ . Accessed March 7, 2022
Garcia P, Han J, Montez-Rath ME, Sun S, Shang T, Parsonnet J, et al.: SARS-cov-2 booster vaccine response among patients receiving dialysis. Clin J Am Soc Nephrol 17: 1036–1038, 2022 35383042
Ducloux D, Colladant M, Chabannes M, Yannaraki M, Courivaud C: Humoral response after 3 doses of the BNT162b2 mRNA COVID-19 vaccine in patients on hemodialysis. Kidney Int 100: 702–704, 2021
Spensley KJ, Gleeson S, Martin P, Thomson T, Clarke CL, Pickard G, et al.: Comparison of vaccine effectiveness against the omicron (B.1.1.529) Variant in hemodialysis patients. Kidney Int Rep 7: 1406–1409, 2022 35434428
Carr EJ, Wu M, Harvey R, Billany RE, Wall EC, Kelly G, et al.: Haemodialysis COVID-19 Consortium, Crick COVID Immunity Pipeline: Omicron neutralising antibodies after COVID-19 vaccination in haemodialysis patients. Lancet 399: 800–802, 2022
U.S. Food & Drug Administration. EUA Authorized Serology Test Performance, 2020. Available at: https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/eua-authorized-serology-test-performance . Accessed June 28, 2021
Schnurra C, Reiners N, Biemann R, Kaiser T, Trawinski H, Jassoy C: Comparison of the diagnostic sensitivity of SARS-CoV-2 nucleoprotein and glycoprotein-based antibody tests. J Clin Virol 129: 104544, 2020
Rossi PH, Wright JD, Anderson AB: Handbook of Survey Research, 1st Ed., edited by Rossi PH, Wright JD, Anderson AB, Cambridge, MA, Academic Press, 2013, pp 145–146
Kristiansen PA, Page M, Bernasconi V, Mattiuzzo G, Dull P, Makar K, et al.: WHO International Standard for anti-SARS-CoV-2 immunoglobulin. Lancet 397: 1347–1348, 2021
Hao L, Naiman D: Quantile Regression, London, Sage Publications, 2007
Marino MF, Farcomeni A. Linear quantile regression models for longitudinal experiments: An overview. METRON 73: 229–247, 2015
Feng S, Phillips DJ, White T, Sayal H, Aley PK, Bibi S, et al.: Oxford COVID Vaccine Trial Group: Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. Nat Med 27: 2032–2040, 2021
Andrews N, Stowe J, Kirsebom F, Toffa S, Rickeard T, Gallagher E, et al.: Covid-19 vaccine effectiveness against the Omicron (B.1.1.529) variant. N Engl J Med 386: 1532–1546, 2022
Centers for Disease Control and Prevention: COVID-19 Vaccines for Moderately or Severely Immunocompromised People, 2022. Available at: https://www.cdcgov/coronavirus/2019-ncov/vaccines/recommendations/immunohtml . Accessed March 14, 2022
Food and Drug Administration: Frequently Asked Questions on the Emergency Use Authorization for Evusheld (Tixagevimab Co-Packaged with Cilgavimab) for Pre-Exposure Prophylaxis (PrEP) of COVID-19, 2022. Available at: https://www.fdagov/media/154703/download . Accessed March 14, 2022